Forum Topic News
  • Conversation: Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy

    • July 18, 2018 12:08 PM BST
    • Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy

      Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for those patients that enroll into the next part of the Phase 3 study, which will evaluate the investigational gene therapy fidanacogene elaparvovec for the treatment of hemophilia B. The interventional portion of this pivotal Phase 3 study will enroll patients who have completed at least six months in the lead-in study. Fidanacogene elaparvovec is the official United States Adopted Name (USAN) and will become the Recommended International Nonproprietary Name (INN) for the therapy formerly known as SPK-9001 and PF-06838435.
      Read more: http://www.worldpharmanews.com/pfizer/4485-pfizer-initiates-pivotal-phase-3-program-for-investigational-hemophilia-b-gene-therapy

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč